Shots:

• The first patient has been dosed in the P-I ANTLER trial evaluating CB-010 in patients with r/r B-NHL. In the dose-escalation part of the study- patients who have failed at least 2L of CT or immunotherapy will receive the therapy following lymphodepletion
• The initial purpose of the dose escalation is to evaluate the safety & tolerability of CB-010 while an expansion part of the study is to evaluate the efficacy of CB-010 in a defined population. The results from the trial are expected in 2022
• CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells which have developed using Caribou’s chRDNA CRISPR technology

  Ref: Businesswire | Image: BioSpace